Pyoderma gangrenosum induced by lenalidomide in a case of multiple myeloma

Ann Hematol. 2020 Feb;99(2):379-380. doi: 10.1007/s00277-019-03846-0. Epub 2019 Dec 10.

Authors

Mathieu Meunier^{1

2}, Ayoub Larabi³, Mathilde Schacherer⁴, Clémence Deteix⁴, Stéphane Courby⁴, Jean Yves Cahn⁴

Affiliations

¹ Department of Clinical Hematology, CHU Grenoble Alpes, Grenoble, France. mmeunier2@chu-grenoble.fr.
² CNRS UMR 5309, INSERM, U1209, Institute for Advanced Bioscience, Université Grenoble Alpes, 38700, Grenoble, France. mmeunier2@chu-grenoble.fr.
³ Department of Clinical Pharmacology, CHU Grenoble Alpes, Grenoble, France.
⁴ Department of Clinical Hematology, CHU Grenoble Alpes, Grenoble, France.

PMID: 31822948
DOI: 10.1007/s00277-019-03846-0

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Dexamethasone / administration & dosage
Drug Substitution
Febrile Neutropenia / etiology
Granulocyte Colony-Stimulating Factor / therapeutic use
Humans
Immunologic Factors / administration & dosage
Immunologic Factors / adverse effects*
Lenalidomide / administration & dosage
Lenalidomide / adverse effects*
Male
Multiple Myeloma / complications
Multiple Myeloma / drug therapy*
Piperacillin, Tazobactam Drug Combination / therapeutic use
Pyoderma Gangrenosum / chemically induced*
Pyoderma Gangrenosum / drug therapy
Pyoderma Gangrenosum / therapy
Thalidomide / analogs & derivatives
Thalidomide / therapeutic use

Substances

Immunologic Factors
Granulocyte Colony-Stimulating Factor
Piperacillin, Tazobactam Drug Combination
Thalidomide
Dexamethasone
pomalidomide
Lenalidomide